INVITED COMMENTARY
Alik Farber, MD, Boston, Mass Although few would argue that revascularization is the cornerstone of treatment for symptomatic peripheral arterial disease, multiple questions about its execution remain unanswered. One such question relates to what tibial target vessel is best revascularized. Traditionally, surgeons chose the target vessel for a surgical bypass based on gestalt rooted in a series of qualitative features, including adequate diameter, length, freedom from calcification, and direct connection to a named foot vessel.
Paramount to the choice of revascularization target was its anticipated technical suitability for a surgical anastomosis. Advent and adoption of endovascular therapy, with associated lack of relevance for surgical target suitability, has brought into question the traditional concepts of the optimal distal target. Serendipitously, the angiosome concept, applied to the lower extremity, offered a rational approach on which to base target choice.
It is intuitive to imagine that revascularizing a target vessel that directly supplies the tissue in most need of improved blood flow makes sense. Multiple studies testing this concept concluded that angiosometargeted revascularization leads to better wound healing and limb salvage rates than indirect revascularization. There is also evidence that the effect of angiosomedirected revascularization may differ across surgical and endovascular treatment strategies.
In their study, Rother et al evaluated the effect of angiosome-based endovascular revascularization on foot circulation. They prospectively measured changes after angiosome-directed and indirect tibial angioplasty in foot macrocirculation using ankle-brachial index and microcirculation using laser Doppler flowmetry and tissue spectrometry. The authors discovered that although there was global improvement in both foot macrocirculation and microcirculation after treatment, there was no differential improvement in specific angiosome microcirculation based on whether revascularization was angiosome directed or not. The presence of diabetes or renal failure did not change these observations. There is no question that this study can and will be criticized for its relatively small numbers and vagaries of design. However, the authors' findings cast a shadow over the presumption that angiosome-based revascularization is crucial.
That the story of optimal revascularization is more complicated than it appears is not surprising. Collateral circulation formed in response to chronic ischemia may lead to better transangiosomal flow than would be anticipated. This fits with the clinical observation that bypass to one part of the foot may successfully treat tissue loss in another. As the authors point out in their discussion, not all studies evaluating the angiosome concept reached the conclusion that angiosome-directed revascularization is essential. Furthermore, many studies supporting the utility of angiosome-directed revascularization may be criticized for small numbers, retrospective design, and lack of adequate covariate adjustment. The Best Endovascular vs Best Surgical Therapy in Patients With Critical Limb Ischemia (BEST-CLI) and Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) 2, prospective, randomized controlled trials evaluating revascularization strategy for critical limb ischemia and currently accruing patients in North America and Europe, may allow for secondary analysis of angiosomedirected vs indirect revascularization and thus provide more data to this controversy. In the meantime, there is no harm in considering angiosomes as one of a number of factors that weigh on the choice of the revascularization target.
